Drug Compound Screening for Dermatomyositis and Systemic Lupus Erythematosus

皮肌炎和系统性红斑狼疮的药物化合物筛选

• 批准号: 7467797
• 负责人: STEVEN A GREENBERG
• 金额: $ 19.25万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7467797
• 关键词: Autoimmune Diseases; Biological Assay; Blood; Blood specimen; Cellular Assay; Cellular biology; Clinical Trials; Dendritic Cells; Dermatomyositis; Development; Disease; Drug Compounding; Enzyme-Linked Immunosorbent Assay; Funding; Immunosuppressive Agents; Inflammatory; Injury; Interferon-alpha; Interferon-beta; Interferons; Lupus Erythematosus; Medical; Methods; Modeling; Molecular; Muscle; Myositis; Natural Immunity; Pathogenesis; Patients; Pharmaceutical Preparations; Process; Production; Research; Research Personnel; Robotics; Screening procedure; Systemic Lupus Erythematosus; Systemic disease; Tissues; United States National Institutes of Health; Validation; Work; assay development; base; drug development; drug discovery; high throughput screening; pre-clinical; small molecule libraries

DESCRIPTION (provided by applicant): Dermatomyositis and systemic lupus erythematosus are autoimmune disorders of uncertain cause and without specific medical therapy, generally treated with non-specific immunosuppressive medications that have significant complications. We have studied muscle and blood samples from patients with dermatomyositis and other inflammatory myopathies, and believe that overproduction of interferon alpha and beta (IFN-a/b) by plasmacytoid dendritic cells is responsible for tissue injury in dermatomyositis specifically. Other investigators studying systemic lupus erythematosus (SLE) have also hypothesized that such overproduction of IFN-a/b is in part responsible for the manifestations of that disease. We propose to use high-throughput drug discovery methods to identify compounds of predicted efficacy for DM and SLE. Development of such compounds into safe and effective drugs for the treatment of DM and SLE is the long-term objective of this work.

描述（由申请人提供）：皮肌炎和全身性红斑狼疮是不确定原因的自身免疫性疾病，没有特定的药物治疗，通常接受非特异性免疫抑制药物治疗，具有重大并发症。我们已经研究了来自皮肌炎和其他炎症性肌病患者的肌肉和血液样本，并认为通过血浆乳清细胞类动物树突状细胞过度生产干扰素α和β（IFN-A/B），负责特定是皮肤肌炎的组织损伤。 其他研究全身性红斑狼疮（SLE）的研究人员还假设，IFN-A/B的这种过量生产是部分原因是该疾病的表现。我们建议使用高通量药物发现方法来识别DM和SLE的预测功效的化合物。这项工作的长期目标是将这种化合物开发为治疗DM和SLE的安全有效药物。